RAG1 and melanoma: The results showed that the BNT162b2 treatments had therapeutic effects in the B16F10 melanoma model in μMT mice that were comparable to that in the C57BL/6 mice (Fig. 4b–d), but had no observed therapeutic effects in Rag1−/− mice (Fig. 4b, c, e), which suggests that the anti-tumor effects of BNT162b2-based cancer therapy is predominantly dependent on T cell responses and less dependent on B cell responses.